AmpliPhi Biosciences to Hold 2017 Third Quarter and Business Update Conference Call on November 14
Source:

BUSINESS WIRE

November 8, 2017

SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will hold a business update conference call on Tuesday, November 14, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

 

Live Call:                                U.S.                866-652-5200

International                 412-317-6060

Passcode                    10114360

Live Webcast:

AmpliPhi IR Website

The webcast replay will be available approximately 2 hours after completion of the call and will be archived for 30 days.

Replay:                                    U.S.                 877-344-7529

International                 412-317-0088

Passcode                    10114360

The replay will be available for 48 hours starting approximately 2 hours after completion of the call.

About AmpliPhi Biosciences

 

AmpliPhi Biosciences Corporation is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi’s lead product candidates target multidrug-resistant Staphylococcus aureus and Pseudomonas aeruginosa, which are included on the WHO’s 2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic-resistance as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information visit www.ampliphibio.com.

Posted in: Finance, Operations

Post a Comment

You must be logged in to post a Comment.

FEEDBACK